溶酶体自噬-NLRP3 炎性小体交汇点的药理学靶点。

Pharmacological targets at the lysosomal autophagy-NLRP3 inflammasome crossroads.

机构信息

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.

CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France; Strasbourg Institute of Drug Discovery and Development (IMS), Strasbourg, France.

出版信息

Trends Pharmacol Sci. 2024 Jan;45(1):81-101. doi: 10.1016/j.tips.2023.11.005. Epub 2023 Dec 14.

Abstract

Many aspects of cell homeostasis and integrity are maintained by the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome. The NLRP3 oligomeric protein complex assembles in response to exogenous and endogenous danger signals. This inflammasome has also been implicated in the pathogenesis of a range of disease conditions, particularly chronic inflammatory diseases. Given that NLRP3 modulates autophagy, which is also a key regulator of inflammasome activity, excessive inflammation may be controlled by targeting this intersecting pathway. However, specific niche areas of NLRP3-autophagy interactions and their reciprocal regulatory mechanisms remain underexplored. Consequently, we lack treatment methods specifically targeting this pivotal axis. Here, we discuss the potential of such strategies in the context of autoimmune and metabolic diseases and propose some research avenues.

摘要

细胞内稳态和完整性的许多方面都由核苷酸结合寡聚结构域(NOD)样受体(NLR)家族包含吡咯烷结构域的 3 号(NLRP3)炎性小体维持。NLRP3 寡聚蛋白复合物在外源和内源性危险信号的刺激下组装。该炎性小体也与多种疾病的发病机制有关,特别是慢性炎症性疾病。鉴于 NLRP3 调节自噬,而自噬也是炎性小体活性的关键调节剂,通过靶向这条相互作用的途径可能可以控制过度炎症。然而,NLRP3-自噬相互作用的特定小生境区域及其相互调节机制仍未得到充分探索。因此,我们缺乏专门针对这一关键轴的治疗方法。在这里,我们将讨论在自身免疫和代谢性疾病的背景下,这些策略的潜力,并提出一些研究途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索